Evaluation of Biochemical Serum Markers for the Diagnosis of Polycystic Ovary Syndrome (PCOS) in Obese Women in Kazakhstan: Is Anti-Müllerian Hormone a Potential Marker?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Systematic review of the literature: estimation of the most common gynecological disorders and associated factors among Kazakhstani adolescents.Future science OA · 2026
   Review
2. Age-Metabolic Profile of Lower Serum Estradiol Among Women in Kazakhstan: A Large National Survey-Based Analytical Study.International journal of environmental research and public health · 2026
   Article
3. Exploring zinc-α2-glycoprotein as a mediator of infertility in polycystic ovarian syndrome: a comparative study from a metabolic perspective.Przeglad menopauzalny = Menopause review · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as